---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157095"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:55:07.285756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1

## Summary
- Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.
- Independent DSMB reviewed all six Cohort 1 subjects and recommended continuation of enrollment.
- Enrollment of Cohort 2 expected to begin in Q4 2025 following positive DSMB recommendation.
- Additional clinical study updates for Cohort 1 subjects planned for Q4 2025.

## SEC filing metadata
- accession: 0001193125-25-157095
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/0001193125-25-157095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/d96075d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157095
- JSON: https://secwatch.observer/filing/0001193125-25-157095.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.